15 results about "Acinus" patented technology

The invention belongs to the field of biological medicines, and particularly relates to application of a medicine for intervening in a mitochondrial pyruvic acid carrier in preparation of a medicine for treating acute pancreatitis and a medicine composition of the medicine. The medicine for intervening in the mitochondrial pyruvic acid carrier can reduce the serum enzyme level, relieve pancreatic pathological injury, inhibit inflammatory response, inhibit calcium overload and protect the mitochondrial function, so that pancreatic acinus cell injury is relieved, the effect of treating acute pancreatitis is achieved, and the medicine has a wide application prospect. The invention provides a new choice for clinically treating acute pancreatitis, and has a good application prospect.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention relates to the technical field of novel application of compounds, in particular to novel application of meclozine and analogues thereof. The invention relates to an application of at least one of meclozine and analogues thereof or pharmaceutically acceptable salts or esters thereof in preparation of drugs for preventing and / or treating pancreatitis. The meclozine and the analogue thereof can obviously improve pancreatic tissue necrosis, inflammatory response and oxidative stress of pancreatitis, inhibit alveolar cell death and improve lung injury caused by pancreatitis, so that the meclozine and the analogue thereof can be used as a medicine for treating pancreatitis.

According to the pancreas exocrine function in-vivo high-resolution monitoring system and monitoring method provided by the invention, exciting light emitted by a laser module (1) is reflected by a scanning galvanometer (21) and then is transmitted through a dichroscope (22); the femtosecond pulse exciting light passing through the dichroscope (22) is focused on a pancreas sample arranged on the objective table (24) by the objective lens (23) and excites a tryptophan two-photon fluorescence signal in the pancreas sample, and the tryptophan two-photon fluorescence signal is collected by the objective lens (23); after being reflected by the dichroscope (22), the femtosecond pulse exciting light is separated from the femtosecond pulse exciting light and then detected by the detector (25), so that a two-photon fluorescence image of tryptophan in the pancreatic sample is obtained, and tryptophan two-photon fluorescence can display pancreatic adenosine zymogen particles. The tryptophan two-photon fluorescence signal is used for carrying out delayed dynamic imaging on a pancreas sample, so that in-vivo, three-dimensional and high-resolution characterization of the pancreas zymogen particle number, distribution polarity, movement tendency and other characteristics can be reflected, and the pancreas exocrine function of the organism can be reflected in real time.

The present application relates to the field of pharmacology, in particular to the use of paeoniflorin-6'-O-benzene sulfonate for improving acinar atrophy, maintaining the stability of gland functional units, and repairing gland secretion function. The paeoniflorin-6'-O-benzene sulfonate can effectively improve the acinar atrophy of diabetic animals, and the effect is significantly better than that of paeoniflorin, and can be used for preparing a medicine for treating xeroma.

The application belongs to the technical field of biotechnology, and discloses application of CRELD2 in preparation of a drug for treating acute pancreatitis. The application constructs Creld2 gene knockout mice and pancreas acinar cell specific Creld2 overexpression mice, and uses caerulein to induce an acute pancreatitis model, so as to clarify the functional role of the Creld2 gene in the caerulein-induced acute pancreatitis, and to prove that Creld2 gene knockout can aggravate pancreas injury, and pancreas acinar cell specific overexpression of Creld2 can reduce pancreas injury. Through the two-way evidence of gene knockout aggravating pancreas injury and gene overexpression reducing pancreas injury, it is firstly proved that CRELD2 has a protective effect on the caerulein-induced acute pancreatitis, and a new strategy for intervention of acute pancreatitis based on CRELD2 is provided.

The invention discloses an N-(quinazoline-4-yl) benzo [d] thiazole-5-amine RIPK2 degradation agent and application of the N-(quinazoline-4-yl) benzo [d] thiazole-5-amine RIPK2 degradation agent, and belongs to the field of medicines. The structural general formula of the N-(quinazoline-4-yl) benzo [d] thiazole-5-amine RIPK2 degradation agent provided by the invention is shown as a formula (I), and the compound comprises an acceptable salt of the N-(quinazoline-4-yl) benzo [d] thiazole-5-amine RIPK2 degradation agent. The N-(quinazoline-4-yl) benzo [d] thiazole-5-amine compound disclosed by the invention has relatively good proliferation inhibition activity on pancreatic cancer cells, shows obvious degradation activity on RIPK2 protein, and is relatively high in safety. Therefore, the compound can be applied to preparation of medicines for treating various RIPK2-mediated diseases, including but not limited to pancreatic ductal adenocarcinoma, pancreatic acicular cell carcinoma and pancreatic neuroendocrine tumor.

The application discloses application of chrysin in preparation of a medicine for treating primary Sjogren's syndrome and belongs to the technical field of biological medicine. The application proves that chrysin can be specifically combined with TNFR2 protein and is a new type of TNFR2 inhibitor through molecular docking, molecular dynamics simulation, CETSA experiment and SPR experiment. Animal experiments show that chrysin can significantly increase the secretion amount of saliva and tear of a mouse model of primary Sjogren's syndrome, reduce the serum SSA and SSB antibody levels, reduce lymphocyte infiltration and acinus atrophy of submandibular glands and lacrimal glands, inhibit the expression of a cytokine INF-gamma, and the drug efficacy is equivalent to that of a positive medicine hydroxychloroquine; chrysin and gaoshunyujin have a synergistic effect, and the improvement effect on primary Sjogren's syndrome is better than that of hydroxychloroquine. The application provides a new medical use of chrysin, and provides a safe and effective prevention and treatment medicine for primary Sjogren's syndrome.

The invention discloses a method for simultaneously extracting various cells of internal and external secretion parts of pancreas, and relates to the technical field of pancreas islet separation and purification. The invention discloses a method for simultaneously extracting various cells of internal and external secretion parts of pancreas. The method comprises the following steps: exposing a target visual field, performing pancreas perfusion, terminating digestion, sieving, performing gradient centrifugation, observing and separating layered cells, sorting pancreas islets, extracting acinus cells and identifying. According to the method, a gradient centrifugation method is adopted, a density gradient environment is constructed through a gradient centrifugation solution based on the difference of different cell densities, and various cells settle to corresponding positions according to self densities, so that efficient separation of islet cells, alveolar cells and impurities (such as adipocytes, digestive enzymes and tissue fragments) is realized, and the separation efficiency of the islet cells, the alveolar cells and the impurities is improved. Finally, different types of cells are obtained, and various cell populations obtained based on the method are high in purity, good in activity and high in yield.

The invention discloses a feed for rapidly inducing high-fat pancreatitis model mouse construction. The feed is prepared by taking ethionine and sodium taurocholate as core inducers, lard and palm oil as basic lipids and cholesterol as a lipid regulator. Wherein the mass ratio of the ethionine to the sodium taurocholate is 3: 5. According to the present invention, by optimizing the ratio of lipid to the inducer to the synergistic component, the new feed formula for constructing the high-fat pancreatitis model mouse is obtained, the high-fat pancreatitis model mouse can be efficiently and stably constructed, and the obtained model mouse can simultaneously show lipid infiltration, acinus pyroptosis and inflammatory factor release, the traditional Chinese medicine composition accords with the multi-strike characteristic of clinical high-fat pancreatitis.

The application belongs to the technical field of biological medicine, and particularly relates to a silicon ion preparation for treating chronic pancreatitis and a preparation method and application thereof. The silicon ion preparation has excellent effects of promoting regeneration of pancreatic acinar cells and inhibiting inflammation and fibrosis of pancreatic tissue. The silicon mineral preparation prepared according to the concentration can be used for treating chronic pancreatitis and preventing fibrosis, and has great application prospects. The silicon ion preparation provided in the embodiment can treat chronic pancreatitis and prevent fibrosis. The active material can significantly treat the activity of pancreatitis cells, so as to form healthy pancreatic tissue. The silicon ion preparation comprises that the concentration of silicon ions in the silicon ion preparation is 5 ppm-800 ppm, and the silicon ion preparation is prepared by releasing silicon ions from a silicon mineral preparation.

The invention relates to the technical field of biological medicine, in particular to application of Trem2 in preparation of medicine for treating and / or preventing acute pancreatitis. Aiming at the internal relation among Trem2, autophagy and pyroptosis of acellular cells in acute pancreatitis, intervention is carried out through targeting Trem2, the autophagy function can be accurately adjusted, pyroptosis of acellular cells can be inhibited, compared with a traditional non-specific treatment method, higher pertinence and effectiveness are achieved, and the treatment effect can be remarkably improved.

The application belongs to the biological field and particularly relates to application of organic medlar polysaccharide in prevention and treatment of pancreatic acinar ductal metaplasia. Through in-vivo animal experiments, it is found that compared with common medlar polysaccharide, the organic medlar polysaccharide can significantly reduce the pancreatic acinar ductal metaplasia lesion area, can be used as a natural preparation for preventing pancreatic acinar ductal metaplasia, effectively improves the pancreatic acinar ductal metaplasia, and is used for reducing the incidence and progress risk of the pancreatic acinar ductal metaplasia.

The application provides a feed additive and application thereof. The feed additive comprises the following components in parts by weight: 20-30 parts of flaxseed, 10-20 parts of perilla seed, 1-2 parts of choline, 0.05-0.15 parts of vitamin E, 0.1-0.2 parts of zinc sulfate, 0.01-0.05 parts of nicotinic acid and 48-68 parts of wheat bran. The feed additive and the feed containing the feed additive provided by the application are used for 6-13 month old non-pregnant cows, the mammary gland development of the cows in puberty is intervened, the growth of the mammary gland fat pad in the period is promoted, the growth and development of the lactiferous duct in the gestation period are provided with a material basis, the number of the lactiferous duct and the acinus is increased, and thus the initial number of the mammary epithelial cells in the lactation period is increased, and the peak milk yield of the cows after delivery is improved.

The application discloses a lactobacillus paracasei CFCFC018, a bacterial agent and application thereof, and belongs to the technical field of microorganisms. Lacticaseibacillus paracasei The lactobacillus paracasei CFCFC018 is isolated from the intestinal contents of a field cat in a semi-agricultural and semi-pastoral area in Inner Mongolia, and the strain can highly express amino acids and neurotransmitters without genetic engineering modification, can significantly reduce the damage of mammary gland alveolar structure in a mouse with mastitis induced by staphylococcus aureus, avoid the thickening of the interalveolar matrix layer of the mammary gland, reduce the number of neutrophil infiltrates, and reduce the damage degree of the mammary gland tissue, and has a certain protective effect on the mammary gland tissue. Researches also show that the strain can reduce the abundance of harmful bacteria in feces, improve intestinal inflammation, and reduce the submucosal edema of the intestinal tract, which provides a new idea for preventing and treating mastitis by regulating the intestinal flora.